Flush with cash from their GLP-1 franchises, Eli Lilly and Novo Holdings have become the most active participants in Series A biotech funding. They are leveraging their deep pockets to stimulate company formation and strategically branch into new therapeutic areas, shaping the next wave of innovation.

With a market cap driven by its obesity drugs, Eli Lilly is making multi-billion dollar acquisitions like Centessa that are mere "rounding errors" for its finances. This strategy allows it to buy into high-potential, next-generation therapeutic areas like the orexin space for a relatively low financial risk, diversifying beyond GLP-1s.

Breakthrough drugs aren't always driven by novel biological targets. Major successes like Humira or GLP-1s often succeeded through a superior modality (a humanized antibody) or a contrarian bet on a market (obesity). This shows that business and technical execution can be more critical than being the first to discover a biological mechanism.

Eli Lilly's recent deal-making reveals an aggressive, multi-modal strategy. It secured an AI partnership for obesity (Nimbus), invested in an AI platform for oncology (InduPro), and spent $1.2B acquiring Ventix Biosciences for its oral inflammation pipeline, demonstrating a broad approach to securing leadership in its focus areas.

Eli Lilly is leveraging its massive GLP-1 drug revenue for a long-term strategic play. Instead of just acquiring single assets, the company is investing in global innovation hubs, supercomputing with NVIDIA, and incubators to build a sustainable innovation backbone, aiming to avoid typical patent cliff-driven downturns.

The long-held belief that solving obesity would create immense wealth is now validated by Eli Lilly's $1T market cap, driven by its GLP-1 weight-loss drugs. This marks a significant shift, as the trillion-dollar club was previously dominated by tech and oil companies.

Eli Lilly's $3.25B acquisition of Colonia is a strategic move to secure future revenue. The company is leveraging massive profits from obesity drugs to buy a potential blockbuster franchise, proactively addressing the eventual patent cliff on its current bestsellers.

Eli Lilly’s astronomical growth is also a forecasting challenge. The company significantly undershot its own sales projections, with its CEO admitting the obesity market is a unique "learning experience." This highlights that demand for GLP-1 drugs represents not just market capture, but the creation of an entirely new, rapidly expanding, and unpredictable market.

A key part of Eli Lilly's R&D strategy is tackling large-scale health problems that currently have no treatments and therefore represent a 'zero-dollar market.' This blue-ocean strategy contrasts with competitors who focus on areas with established payment pathways.